RxDoctor Payments Data

Oswald Rondon, MD

Ophthalmology · Kennewick, WANPI 1285680769

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,400 of the $14,978 with a category attached, or 69.4%. AbbVie accounts for 96.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $13,814 and has fallen 98.4% since, to $228 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,978in general payments, 2019–2025

Across 66 payments — averaging $226.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • Sight Sciences, Inc.$158
  • Alcon$110
  • Glaukos Corporation$75
  • Dompe US, Inc.$52
  • Rayner Intraocular Lenses Limited$46
  • plus $147 from 6 others

What the payments were for

  • Speaking & faculty fees$10,40069%
  • Travel & lodging$3,15321%
  • Food & beverage$1,42510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,978 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$1,033,111
Medicare patients
1,829
Services billed
5,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate95$2,806
Ofloxacin69$719
Ketorolac Tromethamine39$582
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat33$547
Latanoprost43$353
Dorzolamide Hcl20$262
Timolol Maleate16$88

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Kennewick

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →